Moxifloxacin Orion

Moxifloxacin, the active ingredient in Moxifloxacin Orion, is a fluoroquinolone antibiotic presented as an oral tablet for systemic use. It treats a range of bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and skin and skin‑structure infections in adults.

GNH USA supplies Moxifloxacin Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare facilities worldwide.

Moxifloxacin is a broad‑spectrum fluoroquinolone used to treat bacterial infections in the respiratory and skin categories. - Community‑acquired bacterial pneumonia: provides bacterial eradication and clinical improvement. - Acute bacterial sinusitis: reduces sinus infection symptoms and bacterial load. - Acute exacerbation of chronic bronchitis: improves respiratory function and shortens disease course. - Skin and skin‑structure infections: achieves bacterial clearance and promotes wound healing.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Abdominal pain - Rash

Serious or Rare Side Effects: - Tendon rupture or tendinitis - QT interval prolongation leading to arrhythmia - Severe allergic reactions such as anaphylaxis - Clostridioides difficile‑associated colitis - Hepatic dysfunction - Photosensitivity

Before prescribing Moxifloxacin, clinicians should consider several safety aspects. - Assess renal function: adjust therapy if significant impairment exists. - Review cardiac history: monitor QT interval in patients with known prolongation. - Avoid use in individuals with documented fluoroquinolone hypersensitivity. - Use with caution in elderly patients due to increased tendon injury risk. - Discontinue promptly if tendon pain, swelling, or inflammation occurs. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Moxifloxacin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - QT‑prolonging agents (e.g., quinidine, amiodarone, sotalol): increased risk of cardiac arrhythmia. - Antacids or supplements containing magnesium/aluminum: markedly reduce moxifloxacin absorption. - Warfarin: may enhance anticoagulant effect and increase bleeding risk.

Moderate Interactions (Monitor Closely): - Corticosteroids: heightened risk of tendon rupture. - Oral contraceptives: possible reduction in contraceptive efficacy.